Date de publication: 2 mars 2011
Promoteur – Intermédiaire Financier
Gedeon Richter Plc.
Lieu
Description
Financing of R&D programme for the development of new proprietary drugs and biosilimar compounds.
Objectifs
Improving the health of European citizens, increasing the competitiveness and boosting the innovative capacity of European health-related industries and businesses, while addressing global health issues including emerging epidemics, are some of the key objectives of the project. This research addresses not only an unmet medical need but also impacts the quality of life of certain patients. EIB financing of the project encourages research and technological development. In addition, the project would assist Hungary in improving its research capabilities.
Secteur(s)
Montant BEI envisagé (montant approximatif)
Up to EUR 150 million
Coût total (montant approximatif)
Up to EUR 382 million
Aspects environnementaux
R&D activities included in the project will not materially change current practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An Environmental Impact Assessment (EIA), therefore, should not be required by the competent authorities as stated in the EU Directive 97/11 amended by Directive 2003/35.
Passation des marchés
The promoter is a private company, not operating in the utilities sector and therefore not covered by EU Directives on procurement. Procedures followed are in the best interest of the project and satisfactory to the Bank.
Statut
Signé - 14/06/2011
Clause de non-responsabilité
Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).